Skip to main content
. 2020 Jul 22;9(8):1755. doi: 10.3390/cells9081755

Figure 4.

Figure 4

Impact of FGF14 overexpression on cancer progression in vivo. A549-EV and A549-FGF14 OE cells were injected in the right flank of immunodeficient mice. Tumors were harvested after 40 days. (A) Representative photographs of dissected FGF14 overexpressing tumors. (B) Measurement of tumor volume during tumor progression. Quantification of (C) tumor volume and (D) tumor mass after tumor dissection. Revalidation of FGF14 expression in mice tumor samples via (E) qPCR and (F) immunohistochemistry staining. (G) Ki67 staining of proliferating cells within the tumor were (H) counted per high power field using ImageJ (Fiji) Software. Representative pictures of FGF14 and Ki67 staining visualized using Alexa Flour 488 coupled secondary antibody (green). (I) Validation of FGF14 overexpression, apoptosis using antibodies against CASP7 and CASP8 and epithelial marker expressions using antibodies against CLDN1 and CYK18 and mesenchymal marker expressions evaluated by antibodies against CDH2 and CTNNB1. (J) Additional immunohistochemistry staining of epithelial and mesenchymal marker. Representative pictures of epithelial markers (CDH1 and CYK18) and mesenchymal markers (CDH2 and CTNNB1) visualized using Alexa Flour 488 coupled secondary antibody (green). Nuclear DNA was counterstained with DAPI (blue), scale bar 50 µm. Data shown as mean ± standard error of the mean using one-way analysis of variance (n = 7). P-values ≤ 0.05 were considered statistically significant for all analyses. * p ≤ 0.05, *** p ≤ 0.001, and **** p ≤ 0.0001.